Stockhead on MSN4d
Dimerix banks initial $3.2m payment in Japanese pharma licensing deal for kidney drugSpecial Report: Dimerix has received the initial payment of ¥300 million (A$3.2 million) in line with its recently announced ...
Australian healthcare sector leaders believe while progress has been made further work is needed to see more women in senior ...
HotCopper on MSN5d
Dimerix posts modest gain as first Japanese payment for DMX-200 landsDimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries ...
Stockhead on MSN4d
Health Check: Half-price sale as brokers ring the bell on Neuren sharesHealthcare analysts believe that shares in rare neurological share play Neuren Pharmaceuticals are well undervalued after a ...
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his ...
In a report released on February 21, Tanushree Jain from Petra Capital maintained a Buy rating on Dimerix Limited (DXB – Research Report), with ...
Stockhead on MSN11d
Health Check: More, please! When record results are not good enough for expectant investorsInvestor reaction to PolyNovo's (ASX:PNV) half-year numbers shows how even seemingly minor earnings misses can result in a ...
Stockhead on MSN18d
Middle East healthcare expansion opens doors for ASX stocksThe Middle East healthcare sector is undergoing rapid expansion presenting opportunities for ASX-listed pharmaceutical medical device and wellness companies.
Dimerix pursues new product concepts and applies scientific knowledge to the discovery of products from early stage development through to commercialisation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback